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Objective: We sought to determine whether a continuous regional infusion of a local
anesthetic delivered to the operative site would result in decreased levels of
postoperative pain and narcotic requirements for patients who undergo a standard
median sternotomy for cardiac surgery.
Methods: A double-blind, randomized, controlled trial was conducted at a single
center. Patients who were undergoing elective coronary artery bypass graft surgery
alone or combined with laser transmyocardial revascularization received bilateral
intercostal nerve blocks with either ropivacaine or saline. At wound closure, 2
catheters with multiple side openings were inserted percutaneously and placed
directly over the sternum. The same agent (ropivacaine vs saline) was then admin-
istered as a continuous regional infusion for 48 hours through an elastomeric pump.
Requirements for postoperative systemic narcotic analgesics and pain assessment
scores were recorded for 72 hours after the operation. Secondary outcome measures
were hospital length of stay and pulmonary function test results. Pain scores and
narcotic use on the second postoperative day were also compared to avoid the
confounding influence of anesthesia administered at the time of the operation.
Results: The total amount of narcotic analgesia required by the ropivacaine group
was significantly less than that of the control group (47.3 vs 78.7 mg, respectively;
P  .038). The ropivacaine group required less narcotics on postoperative day 2 as
well (15.5 vs 29.4 mg, P  .025). The mean overall pain scores for the ropivacaine
group were significantly less than the mean overall scores for the normal saline
group (1.6 vs 2.6, respectively; P  .005). Patients receiving ropivacaine had a
mean length of stay of 5.2 days compared with 8.2 days for patients in the normal
saline group (P .001). Excluding the data from outliers (length of stay 39 days),
the normal saline group mean length of stay was 6.3 days (P  .01). There was no
difference in assessment of pulmonary function.
Conclusion: Continuous delivery of local anesthetics significantly improved postoper-
ative pain control while decreasing the amount of narcotic analgesia required in patients
who underwent standard median sternotomy. There was also a significant decrease in
hospital length of stay, which is likely to result in significant cost reductions.
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Inadequate pain control after coronary artery bypasssurgery and other thoracic and abdominal opera-tions can result in increased morbidity and hospitallength of stay (LOS).1-4 Many factors have beenfound to contribute to unrelieved pain after anoperation, including the reluctance or inability on
the part of patients to ask for needed pain medication. The
reluctance of physicians to prescribe or the nurses to ad-
minister adequate doses of analgesics also contributes to
inadequate pain control.5,6 Standard management of post-
operative pain is with opioid analgesics, such as morphine
sulfate. However, opioid effects, such as respiratory depres-
sion, nausea, vomiting, decreased gastrointestinal motility,
and peripheral vasodilation, can potentially worsen the pa-
tient’s condition and result in unfavorable outcomes, ex-
tended hospital stays, and increased costs.1-4,7 Conversely,
improved postoperative pain control has been demonstrated
to have numerous physiologic benefits.8,9 In recognition of
the need for improved pain management, the Joint Com-
mission on Accreditation of Healthcare Organizations has
recently developed new standards for the assessment and
management of pain in accredited hospitals and other health
care settings.10 The resurgence of interest in pain control
and the recent attempts to fast-track patients stimulated our
interest in postoperative pain control after routine median
sternotomy, which is routinely used for cardiac surgery.
Multimodal analgesia, the combination of different
modes of delivering analgesia, has been shown to be more
effective than any single method of reducing pain. Multiple
studies with regional anesthesia strategies in combination
with systemic analgesics have demonstrated improved pa-
tient outcomes, including decreased LOS.3,11 One such
strategy, the use of nerve blockade followed by a continuous
infusion of a long-acting local anesthetic at the operative
site, has shown improved outcomes in several randomized
clinical trials.3,11 However, this approach has never been
studied after a standard median sternotomy, which is rou-
tinely used to perform coronary artery bypass surgery and
other cardiac surgery procedures. More than 700,000 me-
dian sternotomies are performed annually in the United
States alone.12 Improved pain control and subsequent im-
proved patient outcomes would provide a substantial na-
tional health care benefit. We report the results of a ran-
domized, double-blind, clinical trial of intercostal nerve
blocks with either ropivacaine (a long-acting local anes-
thetic) or normal saline, followed by continuous regional
infusion of the same agent (saline vs anesthetic) on out-
comes after coronary artery bypass surgery.
Methods
Study Screening and Enrollment
The study population included adult patients who underwent elec-
tive coronary artery bypass graft (CABG) surgery or CABG with
the addition of transmyocardial revascularization (CABG/TMR).
All patients underwent a standard median sternotomy. The exclu-
sion criteria included a left ventricular ejection fraction of less than
35%, severe acute or chronic lung disease, acute or chronic renal
insufficiency (creatinine level of 176.8 mol/L [2.0 mg/dL]),
congestive heart failure, level of liver disease (bilirubin level of
1.8 ie, the upper limit of normal at screening), inadequate
hematologic function (defined as a hemoglobin level of 95 g/L,
white blood cell count of 3.0  109/L, neutrophil count of 1.2
 109/L, and platelet count of 100  109/L), or the inability to
understand and sign an institutional review board-approved con-
sent form. These exclusion criteria were chosen to allow for the
exclusion of high-risk patients who might require prolonged intu-
bation and therefore not be able to complete the study protocol.
Each patient was given a face-to-face detailed study explana-
tion by the surgeon before the initiation of any protocol-mandated
procedure. After informed consent was obtained, patients were
introduced to the visual analog pain scale used to rate their incision
pain on a scale ranging from 0 (no pain) to 10 (maximum pain
imaginable). Study participants were informed that they would
receive intravenous narcotics by means of a patient-controlled
analgesia (PCA) pump. Patients were instructed the day before the
operation on how to use the PCA pump. Patients were also
instructed on the use of a microspirometer and a peak flowmeter.
Baseline measurements of forced expiratory volume in one second
(FEV1) and peak expiratory flow were measured the evening
before operative therapy was started.
This study did not incur any additional cost to the patient. All
costs associated with the cardiac surgery were considered standard
of care and were billed to the patient’s insurance carrier. The
ONQ Pain Relief System (I-Flow Corp, Lake Forest, Calif),
which provides the continuous infusion of local anesthetic or
saline control, was provided by the manufacturer. The local anes-
thetic (ropivacaine [Naropin]; AstraZeneca, Wilmington, Del) was
provided free of cost by the manufacturer. The manufacturers did
not contribute to the design of the study or the correction, analysis,
or interpretation of the data. Also, they did not participate in the
decision to submit the study for publication. The standard hospital
cost for the ONQ7 Pain Relief System, which includes the
catheters and elastomeric pump, priming syringes, and patient
carrying case, is $180 to $375 per patient. The cost for the local
anesthetics in the dose used for the duration of the study is
approximately $80.
Operative Procedures
Anesthetic management was standardized in an attempt to elimi-
nate the effects of different anesthetic regimens on postoperative
pain levels. Short-acting anesthetics were used to minimize the
presence of residual anesthetic agents in the postoperative period.
Patients were medicated on call to the operating room with up to
0.15 mg/kg morphine sulfate administered intramuscularly, 2 to 5
mg of Versed (midazolam HCl; Roche Laboratories, Nutley, NJ)
administered intramuscularly, and scopolamine (American Phar-
maceutical Partners, Schaumburg, Ill). Younger patients received
0.4 mg of intramuscular scopolamine, patients older than 65 years
of age received 0.2 mg of intramuscular scopolamine, and patients
greater than 70 years of age did not receive scopolamine. Induction
of anesthesia was begun with administration of 10 g/kg intrave-
nous fentanyl. In addition, a 0.5 to 3 mg/kg intravenous bolus of
Surgery for Acquired Cardiovascular Disease Dowling et al
1272 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
A
CD
propofol, a 0.2 to 0.3 mg/kg intravenous bolus of etomidate, or a
1 to 2 mg/kg intravenous bolus of sodium thiopental was admin-
istered. Succinylcholine chloride (INN: suxamethonium), 1.5 mg/
kg, was administered for intubation. Pancuronium bromide was
used for defasiculation and maintenance of neuromuscular block-
ade. Maintenance anesthesia was with isoflurane and fentanyl as
needed to maintain the bispectral index (BIS) at less than 50.
During cardiopulmonary bypass (CPB), isoflurane alone was given
to maintain the BIS at less than 50. Before weaning from CPB,
patients received 2 mg of Versed intravenously. After CPB, anes-
thesia was with 25 to 250 g  kg1  min1 isoflurane and
propofol as needed to maintain the BIS at less than 50.
During transportation to the recovery area and for the first 2
hours postoperatively, the patients received 25 to 250 g  kg1 
min1 propofol as needed to maintain adequate sedation for me-
chanical ventilation. Fentanyl (a short-acting opioid) was given as
needed until the patients were awake in the recovery room and able
to use a PCA pump. Morphine sulfate was delivered intravenously
through the PCA pump for 72 hours. Patients who were allergic to
morphine sulfate received meperidine (Demerol; INN: pethidine)
through the PCA pump at equivalent doses. PCA orders were
written stating the loading dose (2-4 mg), the PCA dose (0.6-1.5
mg) with a lockout time (6-10 minutes), the continuous dose (1-4
mg/h), and the dose limit (30 mg maximum) in 4 hours. Patients
did not receive nonsteroidal anti-inflammatory agents. In our ex-
perience these drugs are often stopped because of concerns about
bleeding and especially renal dysfunction. Therefore these drugs
were not used for this study.
CABG was performed by using standard techniques. Laser
TMR was performed in patients who had areas with left ventricular
myocardium that were ischemic but not amenable to bypass graft-
ing. Before wound closure, bilateral intercostal nerve injections
from T1 to T12 were performed by using 20 mL of either 0.2%
ropivacaine (AstraZenca) or normal saline (placebo). After reap-
proximation of the sternum with wires, two 20-gauge catheters
with multiple side openings were placed anterior to the sternum
(Figure 1). These catheters were connected to a pressurized elas-
tomeric pump (ONQ7 Pain relief system, I-Flow Corp) that
contains a flow regulator, which allowed for delivery of placebo or
0.2% ropivacaine at approximately 4 mL/h. These catheters were
removed in both groups after 48 hours. Figure 2 shows the par-
ticipant flow from first contact with study referral staff until
completion of the study.
Assignment of the local anesthetic or placebo was made on the
basis of a random table created in advance of patient enrollment.
All investigators and study staff, including the nurses, were
blinded to the identity of the injected solution. Both drugs were
prepared by the research pharmacy team. There was no difference
in the physical appearance of the study drug or placebo. Ropiva-
caine is a long-acting amide-type local anesthetic that has a chem-
ical structure similar to that of bupivacaine. However, there is
significantly less cardiotoxicity with ropivacaine than with other
similar agents, such as bupivacaine.13
Postoperative Evaluation
All subjects were evaluated postoperatively in the cardiac inten-
sive care unit (ICU) per hospital standard-of-care guidelines. Rou-
tine invasive and noninvasive monitoring was performed. Routine
laboratory tests, chest radiography, and electrocardiographic mon-
itoring were performed per ICU standard-of-care guidelines.
Pain was assessed every 4 hours after the patient was awake
and alert by using the same visual analog scale (VAS) adminis-
tered preoperatively. Patients in both groups received morphine
sulfate intravenously or meperidine intravenously through the
PCA pump, as ordered by the physician. The total amount of
systemic analgesics delivered through the PCA pump in both
groups was recorded. Pulmonary function tests were performed
after extubation and every 4 hours until discharge from the inten-
sive care recovery area and then daily for 3 days by respiratory
therapists trained in the measurement of FEV1 and peak expiratory
flow. Continuous need for supplemental oxygen was based on
clinical evaluation and measures of arterial saturation with pulse
oximetry. All patients were assigned nurses experienced in the care
of patients after cardiac surgery and the conduct of clinical re-
search trials. At the end of each nursing shift, the patient’s as-
signed nurse was asked to fill out a form indicating whether he or
she believed the patient had usual pain levels or improved pain
control on the basis of an overall clinical evaluation.
Study End Points and Statistical Analysis
The primary end points were postoperative requirements for sys-
temic narcotic analgesia and postoperative pain assessment scores
on visual analog pain scales for the first 3 days after the operation.
Our secondary end points were narcotic requirements on the sec-
ond postoperative day; postoperative pulmonary function as mea-
sured on the basis of FEV1 and peak expiratory flow, need for
supplemental oxygen, and time to removal of mechanical assisted
ventilation; total LOS in the ICU; and total LOS in the hospital.
Figure 1. Intraoperative placement of the pressurized elastomeric
pump and catheters.
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Patients were also evaluated for adverse events that occurred after
being enrolled in the study during their hospitalization.
This study was designed to have 80% power to detect a 50%
difference in total morphine equivalent dose between groups, with
a 2-sided significance level set at .05. A sample size of 40 ran-
domized to ropivacaine or normal saline in a 1:1 manner by using
an analysis of variance model with local anesthetic group as the
fixed effect in the model was determined adequate to detect a 50%
difference in means, assuming a ropivacaine group morphine mean
of 30 mg and a control group morphine mean of 60 mg, a common
SD of 30, and a 7.5% dropout rate.
Analysis of variance models with local anesthetic group as a
fixed effect in the model were used to analyze the primary end
points. Repeated-measures analysis of variance models were used
to test for differences between groups over postoperative days 1 to
3 for total morphine and postoperative pain scores. The Mantel-
Haenszel 2 test with standardized midranks was used to analyze
LOS (in days). Analysis of variance models with local anesthetic
group as a fixed effect in the model were used to analyze the
pulmonary function test results and change from baseline data.
Demographic and baseline characteristics were analyzed by using
analysis of variance, whereas differences between categoric pa-
rameters were tested by using either the Pearson 2 or Fisher exact
tests. All parameters had descriptive statistics calculated.
Regression models were used to describe the relationship be-
tween postoperative pain and total morphine. The models were
generated as a descriptive measure of effects within groups and not
intended for inferential distinction among groups.
Nonparametric tests were performed when assumptions for a
parametric test were violated. Specifically, the Wilcoxon rank sum
test was used for between-group testing when analysis of variance
assumptions did not apply. When nonparametric tests were re-
ported, the parametric results were included as confirmation of the
analysis. All inferential and descriptive analyses were performed at
the .05 significance level for a 2-sided test by using SAS (Statis-
tical Analysis Systems) version 8.2 software.
Results
Screening and enrollment for the study began in April 2000
and continued until May 2001. Five patients initially en-
rolled in the study were excluded from evaluation. Two
Figure 2. Participant flow during the study. PCA, Patient-controlled analgesia.
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patients who were randomized to the ropivacaine group
were excluded before treatment because of abnormalities on
the intraoperative echocardiogram (severe mitral regurgita-
tion in one and left ventricular ejection fraction of 35% in
the other). Three patients required prolonged intubation and
received additional sedation. Two of these patients were
randomized to ropivacaine and one to placebo. Because of
the additional sedation, these patients were not able to
operate a PCA pump or perform other outcome measure-
ments.
Participants in the 2 groups were similar in all clinical
and demographic respects (Table 1). The majority of par-
ticipants were male, with a history of hypertension, hyper-
lipidemia, coronary artery disease, and a previous myocar-
dial infarction. There was no difference in the 2 groups in
the use of the left internal thoracic artery or the use of TMR.
All patients had use of the left internal thoracic artery, and
additionally, one patient had use of both internal thoracic
arteries. There was no difference in the incidence of arrhyth-
mias between the 2 groups. Specifically, there was no dif-
ference in the incidence of postoperative atrial arrhythmias.
The ropivacaine group reported significantly less pain
than the normal saline group. The mean overall VAS score
for the ropivacaine group was significantly less than the
mean overall VAS score for the normal saline group (1.6 vs
2.6, P .005). Total narcotic use was significantly less with
the ropivacaine group (all narcotics were converted to mor-
phine equivalence) versus the control group (47.3 vs 78.7
mg, respectively; P  .038). Because patient assessment of
pain in the first 24 hours after surgical intervention might be
influenced by residual anesthetics administered during the
operation, narcotic requirements on postoperative day 2
were also assessed as an independent measure. Significantly
less narcotics were required by the ropivacaine group on
postoperative day 2 (15.5 vs 29.4 mg, P  .025).
In the ropivacaine group the mean LOS was 5.2  1.3
days, with a range of 3 to 7 days. Patients in the control
group had a mean LOS of 8.2  7.9 days, with a range of
4 to 39 days. The ropivacaine group had a significant
decrease in mean LOS compared with the control group (P
 .001). There was one patient in the placebo group who
had a long LOS (39 days). The difference in LOS between
the 2 groups remained significant, even if this datum was
excluded from analysis (5.2  1.3 vs 6.3  2.8 days, P 
.01). Narcotic use, pain score evaluations, and LOS are
summarized in Table 2.
A regression model can be used to graphically demon-
strate the difference between pain scores and narcotic re-
quirements over the study period. These data are presented
in Figure 3. The vertical axis represents an objective eval-
uation of pain, and the horizontal axis represents the total
narcotic use (in morphine equivalents) over the length of the
study. A steeper curve indicates the pain level is less re-
sponsive to the intravenous narcotics that were delivered by
means of the PCA pump. A steeper curve is seen in the
control group, and a relatively flat curve is seen in the
ropivacaine group.
As noted, the patient’s primary nurse indicated at the end
of each shift whether he or she believed that the patient had
usual pain levels or improved pain control. In the group
TABLE 1. Baseline characteristics (per protocol population)
Characteristic
Ropivacaine
(n  16)
Normal saline
(n  19) P value
Age (y), mean (95% CIM) 60 (55-66) 60 (56-64) .861
BSA, mean (95% CIM) 1.9 (1.6-2.2) 2.1 (2.0-2.2) .201
Sex
Male 13 (81.2%) 14 (73.7%)
Female 3 (18.8%) 5 (26.3%)
Smoking status 4 (25.0%) 9 (47.4%) .293
Diabetes mellitus 7 (43.8%) 10 (52.6%) .601
Hypertension 14 (87.5%) 17 (89.5%) 1.000
Myocardial infarction 9 (56.3%) 10 (52.6%) .831
Hyperlipidemia 12 (80.0%) 16 (84.2%) 1.000
History of coronary artery disease 13 (81.3%) 16 (84.2%) 1.000
Prior history of operation 9 (56.3%) 6 (35.3%) .227
Ejection fraction (%) —
35%-45% 6 (37.5%) 7 (38.9%) —
50%-70% 10 (62.5%) 11 (55.8%)
Missing/unknown 0 1 (6.3%)
Time of anesthesia (h:min),
mean (95% CIM)
4:36 (4:08-5:03) 4:31 (4:12-4:50) .748
Time to extubation (h:min),
mean (95% CIM)
8:16 (6:10-10:21) 7:17 (5:01-9:32) .509
CIM, Confidence interval of the mean; BSA, body surface area.
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treated with ropivacaine, pain control was evaluated as
improved in 94% and usual in 6%. In the control group pain
control was evaluated as improved in 54% and usual in
46%. These differences were statistically significant (P 
.01).
There was a trend toward improvement in pulmonary
function tests in the ropivacaine group that did not reach
statistical significance. This trend was seen on the first 3
postoperative days. The mean FEV1 was increased 20% on
postoperative day 1, 14% on postoperative day 2, and 17%
on postoperative day 3 in the treated group. The mean peak
expiratory flow was increased 12% on postoperative day 1,
19% on postoperative day 2, and 10% on postoperative day
3 in the ropivacaine group. There was no difference in need
for supplemental oxygen, time on mechanical-assisted ven-
tilation, or LOS in the ICU.
There was no drug toxicity identified in either group. No
patients were dropped from either arm of the study because
of concerns about drug toxicity. There was no difference in
wound infections or wound healing between the groups
during hospitalization or after discharge. There were no
complications related to placement of the catheters or per-
formance of the intercostal nerve blocks.
Discussion
The effective relief of pain after operative therapies is of
paramount importance to patients and health care providers.
In addition to achieving pain control for humanitarian rea-
sons, there is now increasing evidence that improved post-
operative pain management has significant physiologic ben-
efits. Conversely, inadequate pain control has been shown to
result in an increased incidence of atelectasis and signifi-
cantly lower tissue oxygen levels, which can predispose to
infection.8,9 After ambulatory surgery, inadequate pain con-
trol is one of the leading reasons for hospital readmission.7
Recently, the Joint Commission on Accreditation of Health-
care Organizations has developed new standards for the
assessment and management of pain in accredited hospitals
and other health care settings.10 The new standards defini-
tively acknowledge that pain is a coexisting condition with
a number of diseases and injuries and requires explicit
attention.
More than 750,000 heart operations are performed an-
nually in the United States alone.12 Almost all of these
operations are performed through a standard median ster-
notomy incision. Recent advances in operative therapies
and improved anesthetic techniques have allowed for early
extubation and fast-tracking of these patients. However,
there have been no advances in methods to improve the
control of pain after a median sternotomy. Isolated studies
have advocated the use of epidural or intrathecal anesthetics
in patients who undergo median sternotomy.14,15 However,
these techniques have not been adopted because of concerns
over respiratory depression and epidural hematomas in pa-
tients who require full anticoagulation during surgical in-
tervention.
There has been a resurgence of interest in the use of
continuous administration of local anesthetics to create a
regional field block in other surgical specialties. This ap-
proach has resulted in a significant decrease in pain scores
and narcotic use after elective cesarean delivery.16 Regional
infusion of ropivacaine after colon and rectal surgery has
resulted in significantly improved pain control, decreased
narcotic requirements, and quicker return of bowel func-
tion.11 Improved pain control with this approach has also
been seen after orthopedic surgery, pelvic surgery, and
thoracic operations performed through a standard thoracot-
omy.3,16,17 These studies also demonstrated that the regional
infusion of anesthetic does not increase the incidence of
wound complications. Most studies have shown a trend
toward a lower infection rate, which has been hypothesized
to be due to the antimicrobial action of bupivacaine.18
Regional anesthetics have been used after minimally inva-
sive coronary artery bypass surgery performed through a
limited left anterior thoracotomy incision.19,20 This tech-
nique decreased chest wall pain and had fewer complica-
tions compared with those seen in control subjects. How-
ever, the use of a thoracotomy for cardiac surgery is quite
limited, and the vast majority of patients undergo a median
sternotomy. These studies demonstrate the safety and effi-
cacy of this technique. However, the pharmacokinetics of
continuous regional infusion of anesthesia have not been
well studied. One study showed that low levels of ropiva-
caine are seen in the serum with this technique.17 The use of
regional anesthetic techniques has not previously been de-
scribed after a standard median sternotomy for cardiac
surgery.
This study demonstrates that the use of continuous re-
gional infusion of a long-acting local anesthetic will result
in less pain and less narcotic use after a standard median
TABLE 2. Results of primary end points
Parameter evaluated
Ropivacaine
(n  16)
Normal saline
(n  19) P value
Total morphine (mg) .038
Mean (95% CIM) 47.3 (31.0-63.6) 78.7 (51.1-106.2)
Median 45.1 76.1
Min-Max 2.0-107.0 12.0-263.7
Overall VAS scores,
mean (95% CIM)
1.6 (1.2-2.1) 2.6 (2.1-3.1)
VAS repeated measures
Day .001
Treatment .0195
Day by treatment .9961
LOS, mean (95% CIM) 5.2 (2.2-8.2) 8.2 (5.4-10.9) .001
CIM, Confidence interval of the mean; VAS, visual analog scale; LOS,
length of stay.
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sternotomy for cardiac surgery. In an attempt to provide a
clinical assessment of treatment outcome, the primary
nurses were asked to assess the level of pain control for each
patient. The nurses were blinded to the study and were
significantly more likely to assess the patients in the treated
group as having improved pain control. There was also a
significant decrease in hospital LOS in the treatment group.
Given the high volume of cardiac surgical procedures, any
incremental improvement in LOS will likely result in sub-
stantial cost benefits. This study was powered to show a
difference in postoperative pain levels and narcotic require-
ments, and therefore the small sample size precluded statis-
tical analysis of other outcomes, such as hospital costs. The
actual difference in hospital cost was 8% less in the treated
group. Although the cost data did not reach statistical sig-
nificance, cost savings of this magnitude would result in
substantial national cost benefits. On the basis of an average
cost of $24,000 for coronary artery bypass surgery, a cost
savings of 8% would result in savings of $1.4 billion each
year in the United States alone.
One concern with any new therapy is whether the ap-
proach will be adapted by practicing clinicians. The admin-
istration of bilateral intercostal nerve blocks and placement
of the catheters at operation are straightforward and do not
require the use of new techniques. After the operation, the
elastomeric pump does not require any adjustment or care
by physicians or the nursing staff. Our current practice is to
use this system for essentially all patients who have median
sternotomies. The exception is for patients who we antici-
pate will require prolonged intubation and intravenous se-
dation.
In summary, advances in operative therapy and anes-
thetic techniques have allowed for rapid recovery of patients
after cardiac surgery. These advances, along with the in-
creased emphasis on pain control, have highlighted the need
for improved strategies of pain management after median
sternotomy. In this double-blind, randomized, clinical trial
we demonstrated that the use of continuous infusion of local
anesthetic after standard median sternotomy results in less
postoperative pain, decreased need for systemic narcotics,
and decreased LOS. These results and the large number of
patients who require median sternotomies for cardiac sur-
gery indicate that this approach might provide substantial
national health care benefits.
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